IO Biotech, Inc.

IO Biotech is a clinical-stage biopharmaceutical company pioneering the first-in-class investigational dual-action immune-modulating cancer vaccine with the goal of becoming the backbone of combination therapy for people with cancer. The Company’s T-win® vaccine platform is directed against the tumor microenvironment (TME) and is designed to stimulate T cells against tumor cells and the…More most important immune-suppressive cells in the TME. IO Biotech’s most advanced program for IO102-IO103 is currently in Phase 3 development. IO Biotech is headquartered in Copenhagen, Denmark.